Wire · opportunities
FDA Clears Scholar Rock's SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 September 2026 · Fusion42 review
The FDA approved Scholar Rock's Isembyld, the first treatment targeting muscle loss in spinal muscular atrophy for patients aged two and older who already take certain SMA drugs, with commercial launch in the U.S. starting immediately.
This Wire brief sits within Fusion42's coverage of Biotech, and 9 sources have reported it between 12 Sep 2026 and 14 Sep 2026.
◆ ◆ The Wire takeaway
You can accelerate development plans for SMA adjunct therapies as a new market opens in the U.S. after regulatory hurdles dropped. Your chance to supply supportive muscle treatment alongside nerve-focused SMA drugs just became real.
◆ Coverage
9 sources · first reported 12 Sep 2026 · latest 14 Sep 2026
◆ Related on Wire
◆ Topics